The news for mesothelioma treatment continues reason for hope. Drug researchers from China and the United States are working together on the KDR/Kit Inhibitor, which will work to end the new growth of cancerous cells in patients.
The two companies, China-based Simcere Pharmaceutical Group and OSI Pharmaceuticals in the U.S., are basing the project in China. OSI specializes in the discovery and development of innovative molecular targeted therapies. The drug, called OSI-930 for now, has shown positive results in treating small and non-small cell lung cancer, colorectal, gastric and other cancers. Its effectiveness in treating these cancers has the teams working on its treatment of mesothelioma as well.